Hyris, a wholly owned subsidiary of Ulisse Biomed S.p.A., has signed a distribution agreement with GrowBIGogh, a company based in Gilroy and Salinas, California, which sells technology solutions for the hydroponic gardening and agriculture sector.

The agreement provides for the distribution of the Hyris system by GrowBIGogh in the United States for testing in private companies, laboratories, private clinics, and public entities operating in the cannabis and plant health sectors.
The US cannabis market is expected to reach $42.98 billion in 2024 (Source: Statista Market Insights).

The cannabis market includes products derived from the cannabis plant that are used for medical or recreational purposes. The market includes medical, pharmaceutical, and recreational cannabis, as well as CBD-based products. The medical and pharmaceutical cannabis markets include products used to treat conditions such as chronic pain, mental health disorders, and other medical conditions. The recreational cannabis and CBD product markets include products used for personal or recreational purposes.

GrowBIGogh will distribute a set of molecular test kits in the United States, together with Hyris System, to help cannabis growers maximise productivity and minimise inefficiencies. The unique features of Hyris System as an intelligent, portable and easy-to-use genetic testing solution make this offering viable for a wider range of users.

‘This agreement is in line with Hyris' mission to facilitate access to genetic testing for a growing number of users and contexts,’ said Lorenzo Colombo, CTO of Hyris. ‘It is a demonstration of the recognised performance of Hyris' technological solutions in various business segments and our ability to support leading players in their field of activity.’